Nexentis Technologies Inc. (NXTS): Nasdaq/NYSE listing notice — Save Foods receives Nasdaq deficiency notice for bid price below $1; 180-day cure period

Nexentis Technologies Inc.

Nasdaq letter dated April 25, 2023: common stock bid price below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until October 22, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, may be eligible for a second 180-day period if it meets market value and other initial listing standards.
Failure to regain compliance could result in delisting of SVFD from Nasdaq Capital Market.
No immediate effect on listing; stock continues trading under symbol SVFD pending compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Nexentis Technologies Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 25, 2023, Save Foods, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share, which is the minimum closing bid price required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Notice”). This Notice is a notice of deficiency, not delisting, and has no immediate effect on the

View on SEC.gov

Browse all listing & compliance notices →

Nexentis Technologies Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-013811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.